Cyclerion Therapeutics (CYCN) Total Current Liabilities (2018 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Total Current Liabilities of $900000.0 for Q4 2025, up 24.14% year-over-year from $725000.0 in Q4 2024, and up 782.35% quarter-over-quarter from $102000.0 in Q3 2025.
Cyclerion Therapeutics (CYCN) Total Current Liabilities (2018 - 2025) Analysis & Trends
Cyclerion Therapeutics' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $900000.0 for Q4 2025.
- In Q4 2025, Total Current Liabilities rose 24.14% year-over-year to $900000.0; the TTM figure through Dec 2025 stood at $900000.0 (up 24.14% YoY), while the FY2025 annual figure was $900000.0, up 24.14% from the prior year.
- Total Current Liabilities for Q4 2025 stood at $900000.0, up from $102000.0 in the prior quarter.
- The five-year high for Total Current Liabilities was $11.4 million in Q3 2021, with the low at $43000.0 in Q3 2024.
- The 5-year median for Total Current Liabilities is $762500.0 (2024), against an average of $2.7 million.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 4337.84% in 2022, then tumbled 98.52% in 2023.
- Cyclerion Therapeutics' Total Current Liabilities stood at $526000.0 in 2021, then slumped by 87.07% to $68000.0 in 2022, then surged by 2967.65% to $2.1 million in 2023, then sank by 65.24% to $725000.0 in 2024, then grew by 24.14% to $900000.0 in 2025.
- Business Quant data shows CYCN's Total Current Liabilities at $900000.0 in Q4 2025, $102000.0 in Q3 2025, and $800000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 630.93 Mn |
| 10 | Cyclerion Therapeutics | 13.16 Mn | 9.92 Mn | - | 900,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 900,000.00 |
| Sep 30, 2025 | 102,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | 45,000.00 |
| Dec 31, 2024 | 725,000.00 |
| Sep 30, 2024 | 43,000.00 |
| Jun 30, 2024 | 1.28 Mn |
| Mar 31, 2024 | 1.44 Mn |
| Dec 31, 2023 | 2.09 Mn |
| Sep 30, 2023 | 158,000.00 |
| Jun 30, 2023 | 4.95 Mn |
| Mar 31, 2023 | 140,000.00 |
| Dec 31, 2022 | 68,000.00 |
| Sep 30, 2022 | 8.53 Mn |
| Jun 30, 2022 | 9.85 Mn |
| Mar 31, 2022 | 9.49 Mn |
| Dec 31, 2021 | 526,000.00 |
| Sep 30, 2021 | 11.36 Mn |
| Jun 30, 2021 | 222,000.00 |
| Mar 31, 2021 | 375,000.00 |